{"id":529177,"date":"2021-02-08T11:00:02","date_gmt":"2021-02-08T11:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=529177"},"modified":"2021-02-08T11:00:02","modified_gmt":"2021-02-08T11:00:02","slug":"cytokine-release-syndrome-market-drugs-trends-and-forecast-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cytokine-release-syndrome-market-drugs-trends-and-forecast-by-delveinsight_529177.html","title":{"rendered":"Cytokine Release Syndrome Market Drugs, Trends and Forecast by DelveInsight"},"content":{"rendered":"
\"Cytokine<\/a><\/div>\n

DelveInsight<\/strong> has launched a new report on Cytokine Release Syndrome Market<\/strong><\/a><\/p>\n

 <\/p>\n

Cytokine release syndrome (CRS) is a systemic inflammatory response with outpouring of the inflammatory cytokines due to stimulus triggered by a variety of factors such as infections, immunotherapy, especially those involving T-cell engagers and certain other drugs. Even though cytokines acts to direct immune response, the higher levels of cytokines with increased inflammation can be harmful as they interfere with a number of body functions. In severe cases, CRS can cause organ failure in heart, lung, kidney, liver, and brain function that may even lead to death.<\/p>\n

 <\/p>\n

Request for free sample copy-<\/strong> https:\/\/www.delveinsight.com\/sample-request\/cytokine-release-syndrome-market <\/strong><\/a><\/p>\n

 <\/p>\n

The Cytokine Release Syndrome Market<\/strong> report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cytokine Release Syndrome Market<\/strong><\/p>\n

 <\/p>\n

Cytokine Release Syndrome Market Disease<\/strong><\/p>\n

The main cytokines implicated in the pathogenesis of CRS include interleukin-6 (IL-6), IL-10, tumour necrosis factor (TNF), IL-1, IL-2, IL-8, interferon (IFN)-γ, monocyte chemo attractant protein 1 (MCP-1) and granulocyte-macrophage colony-stimulating factor (GM-CSF) and others. CRS clinically manifests when large numbers of lymphocytes (B cells, T cells, and\/or natural killer cells) and\/or myeloid cells (macrophages, dendritic cells, and monocytes) become activated and release inflammatory cytokines.<\/p>\n

 <\/p>\n

Cytokine Release Syndrome Symptoms<\/strong><\/p>\n

The most widely used grading scheme for the severity of CRS was developed by the National Cancer Institute (NCI). CRS can be classified into following grades:<\/p>\n